Cardiff Oncology, Inc.
CRDF · Biological Products, (No Diagnostic Substances) · 68.4M shares · +23%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$4M (gross $500K, SBC $5M)
Reference price $1.21 · est. market cap ~$83M — last insider purchase, 2026-06-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — deep losses but funded.
Strengths
- Liquidity — current ratio 3.7 (45th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -7732.0%)
- Cash burnNegative free cash flow (-38.0M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +23%/yr over 4y (dilution, book value/share -86%)
- Insider buyingInsider buying — 2 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
- Revenue declineRevenue -83.1% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-8256.3%
Net margin
-7732.0%
Return on equity
-101.0%
Return on assets
-74.1%
Revenue growth (QoQ)
-83.1%
Current ratio
3.7×
Free cash flow
-$38M
EBITDA
-$49M
Tangible book value
$45M
Cash & investments
$67M
Cash runway
7q
Stock comp / revenue
960.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-18 | Mohindru Mani | Buy | 25K | $1.21 |
| 2026-06-18 | PACE GARY W | Buy | 30K | $1.22 |
| 2025-07-30 | PACE GARY W | Buy | 275K | $2.45 |
| 2025-07-30 | PACE GARY W | Buy | 15K | $2.45 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (0)
Suppliers (2)
- Nerviano
- Pfizer Ignite
Named in the 10-K; linked when we track them.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-11 | 0001193125-26-267563 ↗ |
| 8-K | 2026-06-03 | 2026-06-03 | 0001193125-26-254658 ↗ |
| 8-K | 2026-05-29 | 2026-05-27 | 0001193125-26-248711 ↗ |
| 8-K | 2026-05-19 | 2026-05-19 | 0001193125-26-231040 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001213037-26-000013 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001213037-26-000011 ↗ |
| 8-K | 2026-04-09 | 2026-04-06 | 0001193125-26-149623 ↗ |
| 8-K | 2026-04-02 | 2026-03-27 | 0001193125-26-140152 ↗ |
| 8-K | 2026-02-25 | 2026-02-25 | 0001193125-26-068668 ↗ |
| 10-K | 2026-02-24 | 2025-12-31 | 0001193125-26-067464 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001193125-26-067476 ↗ |
| 8-K | 2026-01-27 | 2026-01-27 | 0001193125-26-024375 ↗ |